Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary XXXX .

@entity1 @entity4174 @entity137 @entity417 @entity706 @entity882 @entity231 @entity1036 @entity2592 @entity1897 @entity1398 @entity1891 @entity6537 @entity1011 @entity6688 @entity1499
BACKGROUND: Primary @entity6537 is a rare variant of primary @entity706 for which the optimum treatment strategy remains unknown. METHODS: We performed a retrospective single-center study including @entity1 who underwent uniform management from October 2007 in which @entity1 were offered sequential rituximab, @entity1499 , @entity4174 , and @entity1891 (R- @entity6688 ) followed by binocular radiotherapy and consolidative high-dose @entity2592 . RESULTS: Eleven @entity1 with median age 66 years (range, 48-72) were included. All @entity1 received binocular radiotherapy to a median dose of 36 Gy (range, 30.6-39.6) in 20 fractions. Grade 3+ @entity417 , @entity882 , and @entity1398 occurred in 1 (9%), 2 (18%), and 3 (27%) @entity1 , respectively; raised @entity1011 and @entity1897 occurred in 4 (36%) and 3 (27%) @entity1 , respectively. Grade 3+ ocular @entity137 included @entity231 formation and @entity1036 in 6 (54%) and 3 (27%) @entity1 , respectively. Ten @entity1 (91%) achieved complete response and 1 (9%) partial response. After median follow-up of 4.2 years (range, 1.8-7.6), the median progression-free survival was 3.8 years and the estimated 4-year overall survival was 75.8% (95% CI: 30.5%-93.7%). The initial site of disease progression was the CNS in 4 of 7 @entity1 (57%) and within the eye in 3 of 7 (43%). Five @entity1 achieved responses to salvage therapies. CONCLUSIONS: Combined modality treatment with R- @entity6688 , binocular radiation, and high-dose @entity2592 is effective with moderate @entity137 . Both local and CNS relapses occur; however, the achievement of second and subsequent remissions is possible.
